tci Medicare Compliance & Reimbursement - 2003 Issue 7
Advisory Opinions: OIG NIXES COPAY SUBSIDY
Subscribe or sign in to view the full article.
Article Overview
This article reviews an HHS Office of Inspector General advisory opinion on a pharmaceutical manufacturer’s proposed patient assistance program and its potential interaction with Medicare Part B cost-sharing for certain beneficiaries. It explains why the issue matters for healthcare compliance, drug manufacturers, Medicare beneficiaries, and fraud-and-abuse oversight, and it highlights the broader categories of guidance discussed by the agency, including anti-kickback concerns and alternative assistance approaches.
Why This Topic Matters
The opinion is relevant to compliance, reimbursement, and patient assistance program design because it addresses how manufacturer support for beneficiary out-of-pocket obligations can affect Medicare, competition, and fraud-and-abuse risk.
What You Will Learn
- How an HHS Office of Inspector General advisory opinion can affect manufacturer patient assistance programs
- What broad compliance and fraud-and-abuse issues arise when patient support intersects with Medicare cost-sharing
- What categories of alternatives are discussed for assisting financially needy patients
- How the topic relates to Medicare beneficiary assistance and healthcare program oversight
Who Should Read This
- Compliance officers
- Healthcare attorneys
- Pharmaceutical manufacturers
- Revenue cycle professionals
- Medical coding and billing professionals
- Healthcare administrators
Subscribe or sign in to view the full article.
Thank you for choosing Find-A-Code, please Sign In to remove ads.
Quick, Current, Complete - www.findacode.com